Abstract:
Introduction. Antibiotic resistance, particularly among gram-negative pathogens, has become a
growing challenge in clinical practice. In kidney transplant recipients, the management of infections is
particularly complex due to immunosuppression, increased morbidity and mortality, and the necessity
of using nephrotoxic antibiotics. The concomitant administration of calcineurin inhibitors further
heightens the risk of nephrotoxicity, limiting therapeutic options. This study aims to assess the
antimicrobial resistance patterns of bacterial uropathogens isolated from kidney transplant recipients,
providing evidence to guide the rational selection of antibacterial therapy in this vulnerable population.
Materials and methods. This retrospective study was performed based on reviewing electronic
medical records of renal transplant recipients from Republican Clinical Hospital T. Mosneaga, between
January 1, 2020 and January 1, 2025. Urine bacteriologic examination data on the sensitivity of urinary
bacteria to antibiotics were analyzed. Antimicrobial susceptibility testing was performed using the disk
diffusion method according to the EUCAST guidelines.
Results. According to electronic databases (SIA AMS) 71 hospital admissions among patients who
receive kidney transplant were identified, with 59 episodes of culture-proven urinary tract infection.
The uropathogens were Klebsiella pneumoniae (25), Escherichia coli (15), followed
by Enterococcus sp. (6), Enterobacter cloacae (6), Acinetobacter sp. (3) Proteus sp. (3), and
Pseudomonas aeruginosa (1). Among the 59 isolates, extended-spectrum β-lactamase (ESBL) K.
pneumoniae and, E.coli showed a high resistance to third-generation cephalosporins, extendedspectrum penicillins, and fluoroquinolones. Most bacteria were sensitive to amikacin (44), meropenem
(40), imipenem (36), nitrofurantoin (28), piperacillin/tazobactam (21) fosfomycin (15).
Conclusions. The rising prevalence of multidrug-resistant uropathogens, particularly ESBL-producing
Enterobacterales, underscores the urgent need for tailored antibiotic selection in kidney transplant
recipients. While aminoglycosides, carbapenems, piperacillin/tazobactam, and nitrofurantoin remain
viable therapeutic options, their nephrotoxic potential requires close monitoring, especially in the
context of concurrent immunosuppressive therapy. Regular monitoring of antibiotic susceptibility
patterns and a focused approach to antimicrobial stewardship are key to mitigating the risk of antibiotic
resistance in this vulnerable patient population.
